TaiMed Biologics Inc - ESG Rating & Company Profile powered by AI
The assessment of TaiMed Biologics Inc is prepared by All Street Sevva using leading artificial intelligence. Alternative companies in the rating peer group for TaiMed Biologics Inc are displayed below. The page contains a questions and answers table for TaiMed Biologics Inc.
TaiMed Biologics Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 5.5; made up of an environmental score of 8.0, social score of 3.2 and governance score of 5.3.
5.5
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Novartis AG | 9.2 | High |
| 2 | Daiichi Sankyo Co Ltd | 8.9 | High |
| 808 | Tilray Inc | 5.6 | High |
| 808 | Y-mAbs Therapeutics Inc | 5.6 | High |
| 835 | TaiMed Biologics Inc | 5.5 | High |
| 835 | Animalcare Group PLC | 5.5 | High |
| 835 | Bafna Pharmaceuticals Ltd | 5.5 | High |
| ... | ... | ... | |
| 2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
| 2749 | Zyden Gentec Ltd | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does TaiMed Biologics Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes TaiMed Biologics Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes TaiMed Biologics Inc report the average age of the workforce?
Sign up for free to unlockDoes TaiMed Biologics Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes TaiMed Biologics Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes TaiMed Biologics Inc disclose cybersecurity risks?
Sign up for free to unlockDoes TaiMed Biologics Inc offer flexible work?
Sign up for free to unlockDoes TaiMed Biologics Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes TaiMed Biologics Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes TaiMed Biologics Inc conduct supply chain audits?
Sign up for free to unlockDoes TaiMed Biologics Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes TaiMed Biologics Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes TaiMed Biologics Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes TaiMed Biologics Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes TaiMed Biologics Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes TaiMed Biologics Inc disclose water use targets?
Sign up for free to unlockDoes TaiMed Biologics Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid TaiMed Biologics Inc have a product recall in the last two years?
Sign up for free to unlockDoes TaiMed Biologics Inc disclose incidents of discrimination?
Sign up for free to unlockDoes TaiMed Biologics Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas TaiMed Biologics Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes TaiMed Biologics Inc disclose parental leave metrics?
Sign up for free to unlockDoes TaiMed Biologics Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes TaiMed Biologics Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes TaiMed Biologics Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes TaiMed Biologics Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes TaiMed Biologics Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes TaiMed Biologics Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs TaiMed Biologics Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes TaiMed Biologics Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes TaiMed Biologics Inc disclose its waste policy?
Sign up for free to unlockDoes TaiMed Biologics Inc report according to TCFD requirements?
Sign up for free to unlockDoes TaiMed Biologics Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes TaiMed Biologics Inc disclose energy use targets?
Sign up for free to unlockDoes TaiMed Biologics Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes TaiMed Biologics Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for TaiMed Biologics Inc
These potential risks are based on the size, segment and geographies of the company.
TaiMed Biologics Inc., a biotechnology company, develops, manufactures, and commercializes various drugs for the treatment and prevention of infectious diseases. The company develops and markets Ibalizumab (TMB-355) Intravenous Infusion, a humanized monoclonal antibody for the treatment of HIV-1 infection. It is also developing TMB-355 Intravenous Push, a humanized monoclonal antibody that is in Phase II clinical trials for the treatment of HIV-1 infection; TMB-355 Intramuscular Injection, a humanized monoclonal antibody intramuscular injection, which is in Phase II clinical trials for treating HIV-1; TMB-365, an anti-CD4 recombinant humanized monoclonal antibody, which is in Phase I clinical trials for treating HIV infections; TMB-370, a bispecific neutralizing antibody that is in Phase I clinical trials to treat HIV infections; and TMB-380, a neutralizing HIV-1 antibody. The company was founded in 2007 and is headquartered in Taipei, Taiwan.